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A B S T R A C T
Multiple sclerosis is a chronic, autoimmune disease of the central nervous system, which mainly affects young women
during a reproductive period of life. Since, its symptoms might be significantly affected by pregnancy, in this study we in-
vestigated the development and kinetics of disease in the model of chronic relapsing experimental autoimmune encepha-
lomyelitis (CR-EAE), induced in genetically susceptible Dark Agouti (DA) strain of rats. They were sensitized with bo-
vine brain white matter homogenate (BBH) in complete Freund’s adjuvant during the first, second or third week of
pregnancy, and the disease scores were compared between treatment groups, and identically treated nongravid females.
Additionally, the susceptibility to the induction of EAE was tested in offspring of mothers that during the pregnancy were
sensitized with BBH. The data have shown that pregnancy does not block the induction of EAE, but that it significantly
changes the course of diseases, depending on time of immunization. In rats sensitized during the first week of gestation
the onset of the clinical signs was delayed, but after the delivery the intensity of disease significantly increased. Similar
aggravation, with appearance of monophasic form of disease was observed in the group of rats sensitized during the
third week of gestation. On the contrary, in rats sensitized during the second week of gestation the beneficial effects were
observed, with later onset of attacks, and lower disease score. Furthermore, offspring of these rats after immunization
with BBH developed a monophasic form of EAE of lower intensity, suggesting that some protective factors might be
transferred across the placenta.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system (CNS) with onset typi-
cally in the second to third decade. It is twice as prevalent
in females as in males and mainly affects young women
during a reproductive period of life1,2. Previously, they
were often discouraged from having children, owing to
the potential exacerbation of MS, but current opinion is
that women withMS and healthy women have similar in-
cidences of pregnancy or delivery-related complica-
tions3–5. Even more, disease activity is almost invariably
halted during pregnancy, although after delivery the re-
lapse rate frequently increases6,7, particularly in the post
partum three months8,9. Amelioration or a worsening of
the disease was mostly related with high, or low-estrogen
states, respectively10.
Some of these changes may be explained by a favor-
able immunological shift from a Th1 to Th2 response
during pregnancy, since estrogens inhibit the production
of Th1 proinflammatory cytokines, such as IL-12, TNF-
and IFN-, whereas they stimulate the production of Th2
anti-inflammatory cytokines, such as IL-10, IL-4, and
TGF-9,11,12, but the underlying mechanisms and interac-
tions between the multiple sclerosis and pregnancy are
still investigating.
Since, important basic information about the patho-
genesis of MS and neuro-immuno-endocrine interaction
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during pregnancy came from the animal models of multi-
ple sclerosis, in this study we attempted to investigate a
potential role of prenatal and perinatal pregnancy-re-
lated events on the development of experimental autoim-
mune encephalomyelitis (EAE) in susceptible Dark Agouti
(DA) strain of rats13,14, in which chronic relapsing (CR)
form of EAE might be induced by immunization of rats
with bovine brain white matter homogenate (BBH) in
complete Freund’s adjuvant (CFA)15,16. To elucidate the
effects of stage of pregnancy on the development of
CR-EAE in mothers, active immunization of DA rats was
done in the first, second and third week of pregnancy. Ad-
ditionally, in some groups the reactivity of offspring to
the inducement of EAE was analyzed.
Materials and Methods
Rats
DA rats, aged 6–12 weeks, from our own colony were
used. They were fed on a standard commercial food and
water ad libitum. Female rats were mated with synge-
neic males. The presence of microscopically estimated
sperm in vaginal smears was considered as the first day
of pregnancy. Virgin females of the same age were used
as the controls.
Plan of experiments
Immunization was performed in nonpregnant (con-
trol group) and pregnant DA rats by subcutaneous injec-
tion of 0.1 ml of the bovine brain white matter homoge-
nate (BBH) emulsion in the complete Freund’s adjuvant
(CFA), which according to our previous data was efficient
in the induction of CR-EAE, as previously described15,16.
In pregnant rats immunization was performed on the
1st, 2nd and 3rd week of pregnancy, i.e. on the 5th, 10th or
on the 15th day after matting. Each group consisted of
nine females. During the gestation and until the 35–37th
day after the delivery, they were inspected daily for the
signs of neurological deficits. The data were compared
with the findings in age-matched, nongravid female DA
rats, which were immunized on the same way.
Further, to assess the effects of immunization of mo-
thers on EAE in offspring, pups of mothers immunized
on the second week of pregnancy, were collected and
given for nursing to foster mothers. At the age of 6 weeks
they were immunized by BBH on the same way as the
control, non-gravid females and inspected daily for the
sings of EAE.
Assessment of disease
The severity of disease was clinically assessed accord-
ing to the following criteria: 0 – no symptoms; 1 – flaccid
paralysis of tail; 2 – hind legs paresis; 3 – hind legs paral-
ysis with incontinence and 4 – death of the animal.
Histological examinations were made by hematoxylin-
-eosin staining of formalin-fixed sections of brain and
spinal cord.
Statistical analysis
Significance of differences between the groups and
the controls were determined by Mann-Whitney U test. P
values less than 0.05 were considered statistically signifi-
cant.
Results
The influence of pregnancy on CR-EAE
Control, nonpregnant female DA rats sensitized with
the BBH in CFA developed a chronic relapsing form of
EAE (control groups on Figures 1 – 4). First signs of dis-
ease appeared after a latent period of 8 days and first at-
tack lasted about 5 days. The second, spontaneous re-
lapse appeared on the 18th day and lasted until the 24th
day, when the second remission occurred. Two out of 9
rats (22.2%) died during the first acute attack and 3 out
of 7 (42.8%) during the relapse. Disease was followed by
histopathological changes typical for EAE, such as exten-
sive perivascular infiltrates of mononuclear cells within
spinal cord and brain stem (not shown).
All pregnant rats also developed EAE, but significant,
time-dependent changes were found in the dynamics of
EAE (Figures 1–3). Thus, in females sensitized with
encephalitogen during the first week of gestation the
first signs of diseases were postponed for 1 or 2 days (Fig-
ure 1) and during the first attack only 1 out of 9 rats
(11%) died. During this period the intensity of disease
was slightly decreased, but few days after the delivery
the symptoms of disease aggravated and from 22nd to 30th
day a new strong attack developed, with a high mortality
(4 out of 8 rats died; 50%). Moreover, the second relapse
was significantly higher in intensity in comparison with
the control group of rats (Figure 1; p<0.01).
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Fig. 1. The clinical course of disease in DA rats sensitized during
the first week of gestation, i.e. on the 5th gestational day, by bo-
vine brain homogenate (BBH) in complete Freund’s adjuvant in
comparison with identically treated non-pregnant DA rats of the
similar age. The severity of disease was clinically assessed ac-
cording to the following criteria: 0 – no symptoms; 1 – flaccid pa-
ralysis of tail; 2 – hind legs paresis; 3 – hind legs paralysis with
incontinence and 4 – death of the animal. Each group consisted
of 9 rats. Data are mean +/– SE.
Animals sensitized during the second week of gesta-
tion developed the mildest form of disease, characterized
by a significant delay in onsets of first and second attack,
by a lower intensity of disease and by an earlier termina-
tion in comparison with the control (Figure 2). In this
group, however, the nonspecific adverse effect of hind
legs paralysis on the act of birth was noticed. This led to
the death of 4 out of 9 females (44.4%). The rest of 5 ani-
mals delivered, but were unable to take care of their off-
spring, owing to the appearance of clinical symptoms of
EAE after the delivery.
In pregnant rats, immunized during the third week of
gestation, the first clinical signs of EAE appeared as
usual on the 9th day after active induction (Figure 3).
Owing to this the delivery was undisturbed and occurred
before the onset of the disease. These females, however,
in postpartum period developed the monophasic and not
the relapsing form of disease. Its clinical score was of
high intensity and symptoms lasted for more than 2
weeks. The maximum of the disease was on the 12th day
after active induction of disease. Animals completely re-
covered on the 34th day after active induction, i.e. 2–3 day
later in comparison with the control group (Figure 3).
Mortality in this group was 55% (5 out of 9 animals died).
EAE in offspring of mothers sensitized
during pregnancy
Offspring from mothers immunized during the sec-
ond week of gestation, were collected and given for nurs-
ing to foreign mothers. After sex matching, the group
consisted of 10 weaning females rats that survived the
stress of delivery and separation from the mothers. At
the age of 6 weeks they were immunized with BBH +
CFA and the data were compared with standard control
(Figures 1–4), consisted of virgin female rats obtained
from non-sensitized mothers, which were similarly trea-
ted with encephalitogen. As shown in Figure 4 offspring
of immunized mothers did not develop the chronic re-
lapsing form of EAE, but the monophasic type of disease,
which lasted 2 weeks. The intensity of the disease was
lower than in the control, but 44% of animals died. All
survived animals recovered completely. On the 32nd day
after the first sensitization they were re-sensitized with
BBH, but none of them developed the disease (the data
are not shown).
Discussion
The data point to significant interactions between the
pregnancy-related events and pathogenesis of EAE, con-
firming the widespread literature data about the marked
influence of pregnancy on the development and clinical
stability of multiple sclerosis in humans1–12,17–19. The in-
teractions were clearly dependent on the phase of preg-
nancy, showing that they were influenced by complex
neurocrine-endocrine factors that differently affected the
afferent, central and efferent arm of immune reaction,
activated after the inoculation of encephalitogen. Thus,
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Fig. 2. The clinical course of disease in DA rats sensitized during
the second week of gestation (i.e. on the 10th gestational day) by
bovine brain homogenate (BBH) in complete Freund adjuvant.
Each group consisted of 9 rats. Data are mean +/– SE.
Fig. 3. The clinical course of disease in DA rats sensitized during
the third week of gestation (i.e. on the 15th gestational day) by bo-
vine brain homogenate (BBH) in complete Freund adjuvant.
Each group consisted of 9 rats. Data are mean +/– SE.
Fig. 4. The clinical course of disease of offspring of DA mothers
sensitized during the second week of gestation. Sensitization was
made by bovine brain homogenate (BBH) in complete Freund
adjuvant at the age of 6 weeks. Young were nursed by milk of for-
eign, previously non-immunized mothers. Each group consisted
of 9–10 female rats. Data are mean +/– SE.
in agreement with findings in humans2,19 and pioneer re-
port of Sep~i} et al.19 in this field, our data underline that
pregnancy might have a suppressive and exacerbating ef-
fect on acute demyelinating disease. Sensiti- zation of
pregnant rats during the first week postponed the onset
of EAE (Figure 1), while that made during the second
week of gestation resulted in a typical amelioration of
disease and it’s aggravation after the delivery (Figure 2).
Moreover, in agreement with others20,21 we found that
offspring of these mothers developed a monophasic in-
stead of chronic relapsing form of EAE, as well as that
survivors were resistant to the re-induction of EAE (Fig-
ure 4), suggesting that protection was partially trans-
ferred from mother to their progeny. The later data are
consistent, but slightly different from results obtained by
Dimitrijevi} et al.22, who investigated the effects of preg-
nancy on EAE in the same strain of rats and found the
most pronounced suppression of EAE in offspring of
mothers, which were immunized before gestation and
during lactation and only delayed onset of the disease in
DA progeny after immunization of mothers during preg-
nancy. It should be, however, emphasized that immuniza-
tion protocol and clinical assessment of disease in our
study were different, as well as that we tested only the
reactivity of offspring from mothers, immunized during
the 2nd week of gestation, which exhibited the most sig-
nificant suppressive effects of pregnancy on EAE. More-
over, since in the report of Dimitrijevic et al.22 it was
clearly shown that protective effects in progeny might be
dependent on lactation and not on passive transfer of
anti-myelin basic protein antibodies across the placenta,
it is important to emphasize that in our experiments the
offspring were nursed by foreign mothers, showing that
in their protection participated the additional factors.
Our data need further investigations, but they under-
line the time dependent effect of pregnancy on clinical
course of CR-EAE in DA rats and their offspring. They
are in high agreement with data obtained in remit-
ting-relapsing model of murine EAE, and other experi-
mental models23,24, but unfortunately we can only specu-
late about the underlying mechanisms, which involve
numerous local and systemic pregnancy-induced influ-
ences on the development of CR-EAE. Currently, it is
generally held that the priming and expansion phase of
EAE occurs within the systemic immune compartment,
as well as that the processes of restimulation of my-
elin-reactive T cells occurs in CNS, where encephalito-
genic T cells reencounter their cognate Ag, in the context
of major histocompatibility complex class II molecules
leading ultimately to local inflammation and demyeli-
nation25,26. Process includes specific interaction between
infiltrating T cells and the resident CNS glia cells and
numerous regulatory mechanisms that control the in-
flammation and induce rapid clearance of lymphoid cells
early after disease27. Many of them are under the control
of pregnancy-related factors1–12, 26. Thus, supporting the
role sex steroids in these events it has been shown that
high levels of estrogens and progesterone during EAE
might reduce the presentation ability of dendritic cells28
and induce a favorable immunological shift from a Th1 to
Th2 response11,12,29. Furthermore, in animal models it
was found that estrogen treatment might in spleen and
CNS induce the appearance of regulatory T cells with
suppressive phenotype30,31 and upregulated FoxP3 gene
expression32. Moreover, similar increase in the propor-
tion regulatory T cells was found in the pregnant women
with MS33,34.
Besides, as reported by numerous recent reviews,
short-term beneficial effect of pregnancy on the course of
MS and EAE might be linked with the activity not only
on sex-steroids, but also with other hormones and preg-
nancy-associated substances that participate in creation
of a specific immunosuppressive or immunoregulatory
environment1–5,26,35. It is likely that among them are also
the pregnancy-induced changes in the liver, such as in-
creased production of acute phase proteins, as well as the
generation of cytotoxic NKT, which in EAE might have a
protective role36,37. Emphasizing the participation of
these mediators in gestation, on the 16th day of syngeneic
pregnancy we found a high accumulation of NKT cells in
the maternal liver38 and a marked upregulation of me-
tallothioneins (MTs) I+II in the liver and at the feto-
placental unit. Similarly, during CR-EAE in DA rats we
found enhanced expression of MT I+II both in the liver
and in the CNS (manuscript in preparation), but al-
though these data suggest that these stress proteins
might also influence the outcome of autoimmune disease
in mothers and their progeny, this speculation needs to
be clarified by further experiments.
In conclusion, in the model of CR-EAE in DA rats we
showed that pregnancy-associated events might signifi-
cantly change the dynamics of disease in mothers, as well
as in their offspring, resulting (depending on the time of
sensitization) in amelioration of the clinical symptoms
(during pregnancy) and in worsening of disease (in the
postpartum period). Since CR-EAE is very similar to
multiple sclerosis in humans the data might be of impor-
tance for the women of reproductive age with MS.
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UTJECAJ TRUDNO]E NA RAZVOJ I TIJEK KRONI^NOG RELAPSIRAJU]EG
EKSPERIMENTALNOG AUTOIMUNOG ENCEFALOMIJELITISA U [TAKORA:
IMPLIKACIJE ZA MULTIPLU SKLEROZU
S A @ E T A K
Multipla skleroza (MS) je kroni~na autoimuna, demijeliniziraju}a bolest sredi{njeg `iv~anog sustava, koja najvi{e
poga|a mla|e `ene u reproduktivnoj `ivotnoj fazi. Budu}i da su tijekom trudno}e opisane zna~ajne promjene u simpto-
matologiji i tijeku MS, u ovom radu smo nastojali primjenom animalnog modela kroni~no relapsiraju}eg autoimunog
encefalitisa (KR-EAE) istra`iti kako pojedine faze trudno}e utje~u na razvoj bolesti. Bolest je inducirana u genetski
osjetljivih DA {takora imunizacijom s homogenatom bijele tvari gove|eg mozga (BBH) u kompletnom Freundovom
adjuvansu (CFA), koji se injicirao tijekom prvog, drugog ili tre}eg tjedna trudno}e. Procjenjivala se klini~ka slika bolesti
tijekom 37 dana nakon imunizacije, kao i mogu}nost indukcije EAE u potomaka majki, koje su tijekom trudno}e bile
imunizirane na encefalitogen. Rezultati su pokazali da trudno}a ne zaustavlja razvoj bolesti, ali da ima zna~ajan modu-
lacijski u~inak na klini~ki tijek KR-EAE, koji ovisi o vremenu izvr{ene imunizacije. U `enki senzibiliziranih tijekom
prvog tjedna gestacije pojava prvih klini~kih znakova bila je odgo|ena, ali su nakon okota intenzitet i trajanje bolesti
bili zna~ajno ve}i. Sli~no pogor{anje klini~ke slike, sa pojavom monofaznog oblika bolesti produ`enog trajanja utvr|eno
je i u `enki senzibiliziranih tijekom tre}eg tjedna gestacije. Nasuprot tome, u gravidnih `enki senzibiliziranih tijekom
drugog tjedna gestacije uo~ena je najve}a odgoda prvih znakova i najkra}i tijek bolesti. Osim toga, mladi ovih majki
(koje su dojile zdrave `enke), su nakon imunizacije s encefalitogenom u dobi od 6 tjedana, razvili monofazni, a ne
kroni~no relapsiraju}i eksperimentalni autoimuni encefalomijelitis, sugeriraju}i da se neki od protektivnih ~imbenika
prenose transplacentarnim putem.
V. Barac-Latas et al.: Experimental Autoimmune Encephalomyelitis and Pregnancy, Coll. Antropol. 34 (2010) Suppl. 1: 267–271
271
